Isecarosmab

• CAT Number: I041598
• CAS Number: 2254082-79-4
• Purity: ≥95%

Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life[1][2][3].
Isecarosmab binds ADAMTS-5, but not ADAMTS-1, ADAMTS-4 and ADAMTS-15[1].
Isecarosmab (1-100 nM, 5 days) decreases huARGS, exAGNxI and GAG after pro-inflammatory stimulation in the bovine and OA human cartilage explants[1].
Isecarosmab (24-72 h) blocks ADAMTS-5-mediated DCS TLR2 activation[2].
Isecarosmab (0.1-10 mg/kg mg/kg, s.c, every third day) decreases the medial cartilage degeneration in Medial meniscus (DMM) mice[1].

Reference

[1]. Siebuhr AS, et al. The Anti-ADAMTS-5 Nanobody® M6495 Protects Cartilage Degradation Ex Vivo. Int J Mol Sci. 2020 Aug 20;21(17):5992.
 [Content Brief]

[2]. Sharma N, et al. Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors. Osteoarthritis Cartilage. 2020 May;28(5):658-668.
 [Content Brief]

[3]. C. Brenneis. Structural and symptomatic benefit of a half-live extended, systemically applied anti-ADAMTS-5 inhibitor (M6495). 2018. 26 (1), S299-S300.